- Previous Close
2.9700 - Open
2.9500 - Bid 2.9300 x --
- Ask 2.9900 x --
- Day's Range
2.9300 - 3.0000 - 52 Week Range
2.1400 - 3.8550 - Volume
528,982 - Avg. Volume
857,088 - Market Cap (intraday)
592.275M - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
19.87 - EPS (TTM)
0.1500 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield 0.13 (4.21%)
- Ex-Dividend Date Mar 27, 2025
- 1y Target Est
3.81
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
www.clinicallabs.com.au4,900
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: ACL.AX
View More
Performance Overview: ACL.AX
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACL.AX
View MoreValuation Measures
Market Cap
590.29M
Enterprise Value
884.79M
Trailing P/E
19.37
Forward P/E
14.35
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.82
Price/Book (mrq)
3.50
Enterprise Value/Revenue
1.23
Enterprise Value/EBITDA
4.82
Financial Highlights
Profitability and Income Statement
Profit Margin
4.21%
Return on Assets (ttm)
7.11%
Return on Equity (ttm)
18.56%
Revenue (ttm)
728.27M
Net Income Avi to Common (ttm)
30.67M
Diluted EPS (ttm)
0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
21.57M
Total Debt/Equity (mrq)
186.45%
Levered Free Cash Flow (ttm)
167.42M